Dr’s team Simon Turcotte, researcher at the Institute, obtained a first grant from $ 675,000 from the granting body BioCanRx and a second grant of $ 1,800,000 from US biotech Iovance Biotherapeutics </ i> . To this is added financial support of nearly $ 1M from the Montreal Cancer Institute, as part of this major project carried out in collaboration with the CRCHUM and the CHUM.
Dr. Turcotte’s team wants to improve the effectiveness and simplify immunotherapy to treat skin cancer and other types of cancer. Rather than giving indiscriminate patients all the T cells that infiltrate their tumors, the most combative T cells will be selected using a cell sorter acquired in 2018 and funded by the Institute. This state-of-the-art device uses a closed system that keeps cells sterile and thus ensures the safety of patients who will receive the transfusion. This method shortens the production time of a transfusion enriched with “anti-cancer soldiers”. A great step forward for patients with metastatic skin cancer who no longer respond to standard treatments and who are looking for valid alternatives.
Francis Rodier and Nicolas Malaquin make discovery that helps target inflammation-related cancers
12 August 2020
Francis Rodier and Nicolas Malaquin make a promising discovery that could reveal new avenues for targeting certain cancers linked to […]
Preventing cells from aging: the discovery of Gerardo Ferbeyre and Sebastian Igelmann
17 January 2022
Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author […]